Clear cell renal cell carcinoma (ccRCC) is one of the few adult cancers for which the VEGF-pathway targeted inhibitors consistently show substantial objective response rates, and it is characterized by loss of VHL gene product function (Shulman, Shi, & Zhang, 2021). This evidence concerns the gene VHL and cancer.